Inhaled Surfactant Therapy in Newborns in Artificial Lung Ventilation

Objective: to evaluate the efficiency of inhaled surfactant therapy in neonatal infants with respiratory failure.Subjects and methods. The trial enrolled 13 premature neonatal infants; their mean gestational age was 31.8±2.8 weeks and the birth weight was 1825±600.9 g. They had a oneminute Apgar sco...

Full description

Saved in:
Bibliographic Details
Main Authors: S. A. Perepelitsa, A. A. Luchina
Format: Article
Language:English
Published: Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology, Moscow, Russia 2014-10-01
Series:Общая реаниматология
Subjects:
Online Access:https://www.reanimatology.com/rmt/article/view/1420
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1839578435173744640
author S. A. Perepelitsa
A. A. Luchina
author_facet S. A. Perepelitsa
A. A. Luchina
author_sort S. A. Perepelitsa
collection DOAJ
description Objective: to evaluate the efficiency of inhaled surfactant therapy in neonatal infants with respiratory failure.Subjects and methods. The trial enrolled 13 premature neonatal infants; their mean gestational age was 31.8±2.8 weeks and the birth weight was 1825±600.9 g. They had a oneminute Apgar score of 4.3±1.4. All the neonates needed mechanical ventilation (MV) atbirth because the leading clinical sign was respiratory failure caused by acute intranatal hypoxia, neonatal amniotic fluid aspiration, respiratory distress syndrome (RDS), and cerebral ischemia. Curosurf was injected in a dose of 174.7±21 mg/kg in the infants with neonatal RDS at 35 minutes of life. All the babies included in the study were noted to have severe disease and prolonged MV. After stabilization of their status, the neonates received combination therapy involving surfactantBL inhalation to reduce the duration of MV. The dose of the agent was 75 mg. Results. After surfactantBL inhalation, effective spontaneous respiration occurred in 69.2% of the newborn infants; successful extubation was carried out. The median duration ofMV after surfactant BL inhalation was 22 hours (4—68 hours). There were no reintubated cases after inhalation therapy. Following surfactantBL inhalation, 4 (30.8%) patients remained to be on MV as a control regimen; 3 of them had highfre quency MV. SurfactantBL inhalation made it possible to change the respiratory support regimen and to reduce MV parame ters in these babies.
format Article
id doaj-art-6f488d1710e941f99b010f09801f74b1
institution Matheson Library
issn 1813-9779
2411-7110
language English
publishDate 2014-10-01
publisher Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology, Moscow, Russia
record_format Article
series Общая реаниматология
spelling doaj-art-6f488d1710e941f99b010f09801f74b12025-08-04T10:40:42ZengFederal Research and Clinical Center of Intensive Care Medicine and Rehabilitology, Moscow, RussiaОбщая реаниматология1813-97792411-71102014-10-01105445110.15360/1813-9779-2014-5-44-511418Inhaled Surfactant Therapy in Newborns in Artificial Lung VentilationS. A. Perepelitsa0A. A. Luchina1V. A. Negovsky Research Institute of General Reanimatology, Russian Academy of Medical Sciences, Moscow, Russia Immanuel Kant Baltic Federal University, Kaliningrad, RussiaKaliningrad Regional Maternity Hospital One, Kaliningrad, RussiaObjective: to evaluate the efficiency of inhaled surfactant therapy in neonatal infants with respiratory failure.Subjects and methods. The trial enrolled 13 premature neonatal infants; their mean gestational age was 31.8±2.8 weeks and the birth weight was 1825±600.9 g. They had a oneminute Apgar score of 4.3±1.4. All the neonates needed mechanical ventilation (MV) atbirth because the leading clinical sign was respiratory failure caused by acute intranatal hypoxia, neonatal amniotic fluid aspiration, respiratory distress syndrome (RDS), and cerebral ischemia. Curosurf was injected in a dose of 174.7±21 mg/kg in the infants with neonatal RDS at 35 minutes of life. All the babies included in the study were noted to have severe disease and prolonged MV. After stabilization of their status, the neonates received combination therapy involving surfactantBL inhalation to reduce the duration of MV. The dose of the agent was 75 mg. Results. After surfactantBL inhalation, effective spontaneous respiration occurred in 69.2% of the newborn infants; successful extubation was carried out. The median duration ofMV after surfactant BL inhalation was 22 hours (4—68 hours). There were no reintubated cases after inhalation therapy. Following surfactantBL inhalation, 4 (30.8%) patients remained to be on MV as a control regimen; 3 of them had highfre quency MV. SurfactantBL inhalation made it possible to change the respiratory support regimen and to reduce MV parame ters in these babies.https://www.reanimatology.com/rmt/article/view/1420neonatal infantssurfactant inhalationneonatal aspirationcongenital pneumonia
spellingShingle S. A. Perepelitsa
A. A. Luchina
Inhaled Surfactant Therapy in Newborns in Artificial Lung Ventilation
Общая реаниматология
neonatal infants
surfactant inhalation
neonatal aspiration
congenital pneumonia
title Inhaled Surfactant Therapy in Newborns in Artificial Lung Ventilation
title_full Inhaled Surfactant Therapy in Newborns in Artificial Lung Ventilation
title_fullStr Inhaled Surfactant Therapy in Newborns in Artificial Lung Ventilation
title_full_unstemmed Inhaled Surfactant Therapy in Newborns in Artificial Lung Ventilation
title_short Inhaled Surfactant Therapy in Newborns in Artificial Lung Ventilation
title_sort inhaled surfactant therapy in newborns in artificial lung ventilation
topic neonatal infants
surfactant inhalation
neonatal aspiration
congenital pneumonia
url https://www.reanimatology.com/rmt/article/view/1420
work_keys_str_mv AT saperepelitsa inhaledsurfactanttherapyinnewbornsinartificiallungventilation
AT aaluchina inhaledsurfactanttherapyinnewbornsinartificiallungventilation